# US 2022/0017972 A1 · Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017972 A1
- Document ID: US20220017972A1
- Status: Published application
- Kind: A1
- Application number: 17/381,272
- Filed: 2021-07-21
- Published: 2022-01-20
- Earliest claimed: 2012-06-07
- Assignees: Institut Curie; INSERM(Institut National de la Sante et de la Rcherche Medicale)
- Applicants: Institut Curie; INSERM(Institut National de la Sante et de la Rcherche Medicale)
- Inventors: Marc-Henri Stern; Elodie Manie; Tatiana Popova
- Web page: https://patentgrep.com/patent/US20220017972A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/131: acyclic
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/282: Platinum compounds
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 33/243: Platinum; Compounds thereof
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.

## Claims

### Claim 1

A method for treating cancer, the method comprising a therapeutically effective amount of a PARP inhibitor and/or an alkylating agent to a human patient identified as having, in a tumor sample obtained from the patient, a number, per genome, of large scale transitions (LSTs) greater than a predetermined threshold number of LSTs, wherein an LST is a breakpoint between two genomic regions of different copy number, each such genomic region greater than or equal to 3 and less than 6 megabases long.

### Claim 2 (depends on 1)

The method of claim 1, wherein said PARP inhibitor and/or alkylating agent is selected from the group consisting of iniparib, olaparib, rucaparib, CEP 9722, MK 4827, BMN-673, 3-aminobenzamide, platinum complexes, chlormethine, chlorambucil, melphalan, cyclophosphamide, ifosfamide, estramustine, carmustine, lomustine, fotemustine, streptozocin, busulfan, pipobroman, procarbazine, dacarbazine, thiotepa and temozolomide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is selected from breast cancer, ovary cancer, pancreas cancer, head and neck carcinoma and melanoma.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is breast cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is basal-like breast cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient is identified by detecting, in the tumor sample, the number of LSTs per genome.

### Claim 7 (depends on 6)

The method of claim 6, wherein the number of LSTs per genome is detected by detecting copy number for at least 500 Single Nucleotide Polymorphism (SNP) loci.

### Claim 8 (depends on 6)

The method of claim 6, wherein the number of LSTs per genome is detected by detecting copy number for at least 3,000 Single Nucleotide Polymorphism (SNP) loci.

### Claim 9 (depends on 6)

The method of claim 6, wherein the number of LSTs per genome is detected by comparative genomic hybridization (CGH) array, Single Nucleotide Polymorphism (SNP) array, or sequencing of polymorphic loci.
